# US 2020/0246482 A1 · Anticancer drug-containing plant virus particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0246482 A1
- Document ID: US20200246482A1
- Status: Published application
- Kind: A1
- Application number: 16/854,444
- Filed: 2020-04-21
- Published: 2020-08-06
- Earliest claimed: 2015-06-29
- Assignees: Case Western Reserve University; Massachusetts Institute of Technology
- Applicants: Case Western Reserve University; Massachusetts Institute of Technology
- Inventors: Nicole F. Steinmetz; Stephen J. Lippard; Anna Czapar; Yaorong Zheng
- Web page: https://patentgrep.com/patent/US20200246482A1

## CPC

- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 39/12: Viral antigens
- A61P 35/00: Antineoplastic agents
- A61K 2039/585: {wherein the target is cancer}
- C12N 2750/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/12023: Virus like particles [VLP]
- C12N 2770/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/00042: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2770/32022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/32023: Virus like particles [VLP]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.

## Claims

### Claim 1

An anticancer virus particle, comprising a filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle.

### Claim 2 (depends on 1)

The anticancer virus particle of claim 1, wherein the plant virus particle is a filamentous plant virus particle.

### Claim 3 (depends on 2)

The anticancer virus particle of claim 2, wherein the filamentous plant virus particle the Alphaflexiviridae family.

### Claim 4 (depends on 2)

The anticancer virus particle of claim 2, wherein the filamentous plant virus belongs to the Potato virus X species.

### Claim 5 (depends on 1)

The anticancer virus particle of claim 1, wherein the plant virus particle is a rod-shaped plant virus particle.

### Claim 6 (depends on 5)

The anticancer virus particle of claim 5, wherein the plant virus particle is a member of the Virgaviridae family.

### Claim 7 (depends on 5)

The anticancer virus particle of claim 5, wherein the plant virus particle is a tobacco mosaic virus.

### Claim 8 (depends on 1)

The anticancer virus particle of claim 1, wherein the exterior surface of the plant virus particle has been PEGylated.

### Claim 9 (depends on 1)

The anticancer virus particle of claim 1, wherein the anticancer agent is a cationic anticancer agent.

### Claim 10 (depends on 9)

The anticancer virus particle of claim 9, wherein the anticancer agent is a platinum-based anticancer agent.

### Claim 11 (depends on 9)

The anticancer virus particle of claim 9, wherein the anticancer agent is phenanthriplatin.

### Claim 12 (depends on 9)

The anticancer virus particle of claim 9, wherein the cationic anticancer agent is non-covalently encapsulated in the interior of the plant virus particle.

### Claim 13 (depends on 1)

The anticancer virus particle of claim 1, wherein the anticancer agent is covalently conjugated to the interior of the plant virus particle.

### Claim 14 (depends on 1)

The anticancer virus particle of claim 1, wherein a targeting ligand is attached to the exterior of the plant virus particle.

### Claim 15

A method of treating cancer in a subject identified as having cancer by administering to the subject a therapeutically effective amount of an anticancer virus particle, comprising a filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer is ovarian cancer, colon cancer, brain cancer, or breast cancer.

### Claim 17 (depends on 15)

The method of claim 15, wherein the anticancer virus particle is administered together with a pharmaceutically acceptable carrier.

### Claim 18 (depends on 15)

The method of claim 15, wherein the plant virus particle is a filamentous plant virus particle.

### Claim 19 (depends on 15)

The method of claim 15, wherein the plant virus particle is a rod-shaped plant virus particle.

### Claim 20 (depends on 15)

The method of claim 15, wherein the exterior surface of the plant virus particle has been PEGylated.

### Claim 21 (depends on 15)

The method of claim 15, wherein the anticancer agent is a cationic anticancer agent.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cationic anticancer agent is non-covalently encapsulated in the interior of the plant virus particle.

### Claim 23 (depends on 21)

The method of claim 21, wherein the anticancer agent is a platinum-based anticancer agent.

### Claim 24 (depends on 21)

The method of claim 21, wherein the anticancer agent is phenanthriplatin.

### Claim 25 (depends on 15)

The method of claim 15, wherein the anticancer agent is covalently conjugated to the interior of the plant virus particle.

### Claim 26 (depends on 15)

The method of claim 15, wherein a targeting ligand is attached to the exterior of the plant virus particle.
